Cipla, Macleods HIV child treatments approved in South Africa

Published On 2022-06-27 07:00 GMT   |   Update On 2022-06-27 07:00 GMT

New Delhi: South Africa, which has the world's biggest number of people infected with HIV, has approved Cipla Ltd.'s quadrimune, a treatment for children infected with the virus, for use.Quadrimune comes in the form of sweet-tasting granules that can be sprinkled on soft food or dissolved in mill or water, the South African Health Products Regulatory Authority said in a statement on Friday....

Login or Register to read the full article

New Delhi: South Africa, which has the world's biggest number of people infected with HIV, has approved Cipla Ltd.'s quadrimune, a treatment for children infected with the virus, for use.

Quadrimune comes in the form of sweet-tasting granules that can be sprinkled on soft food or dissolved in mill or water, the South African Health Products Regulatory Authority said in a statement on Friday.

The treatment combines four antiretroviral treatments.

Read also: Cipla, DNDi unveil 4-in-1 ARV formulation for kids with HIV

Dolutegravir tablets, made by Macleods Pharmaceuticals Ltd., for the treatment of children with HIV, were also registered for use.

About 13% of South Africa's population, or 8.2 million people, are infected with HIV, according to the national statistics agency.

Read also: Cipla to purchase 21.05 percent stake in Achira Labs to develop affordable medical kits in India







Tags:    
Article Source : Bloomberg

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News